Cyclophosphamide for severe T-DXd-induced interstitial lung disease in low-HER2 breast cancer: a case report and mechanistic insights
{{output}}
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that has shown significant efficacy in treating both HER2-positive and low-HER2 breast cancers. However, interstitial lung disease (ILD) remains a maj... ...
